BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34060483)

  • 1. Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs.
    Solagna F; Tezze C; Lindenmeyer MT; Lu S; Wu G; Liu S; Zhao Y; Mitchell R; Meyer C; Omairi S; Kilic T; Paolini A; Ritvos O; Pasternack A; Matsakas A; Kylies D; Wiesch JSZ; Turner JE; Wanner N; Nair V; Eichinger F; Menon R; Martin IV; Klinkhammer BM; Hoxha E; Cohen CD; Tharaux PL; Boor P; Ostendorf T; Kretzler M; Sandri M; Kretz O; Puelles VG; Patel K; Huber TB
    J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 34060483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated expression of activins promotes muscle wasting and cachexia.
    Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
    FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
    Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal regulatory protein alpha initiates cachexia through muscle to adipose tissue crosstalk.
    Wu J; Dong J; Verzola D; Hruska K; Garibotto G; Hu Z; Mitch WE; Thomas SS
    J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1210-1227. PubMed ID: 31507080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEF2c-Dependent Downregulation of Myocilin Mediates Cancer-Induced Muscle Wasting and Associates with Cachexia in Patients with Cancer.
    Judge SM; Deyhle MR; Neyroud D; Nosacka RL; D'Lugos AC; Cameron ME; Vohra RS; Smuder AJ; Roberts BM; Callaway CS; Underwood PW; Chrzanowski SM; Batra A; Murphy ME; Heaven JD; Walter GA; Trevino JG; Judge AR
    Cancer Res; 2020 May; 80(9):1861-1874. PubMed ID: 32132110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compression of morbidity in a progeroid mouse model through the attenuation of myostatin/activin signalling.
    Alyodawi K; Vermeij WP; Omairi S; Kretz O; Hopkinson M; Solagna F; Joch B; Brandt RMC; Barnhoorn S; van Vliet N; Ridwan Y; Essers J; Mitchell R; Morash T; Pasternack A; Ritvos O; Matsakas A; Collins-Hooper H; Huber TB; Hoeijmakers JHJ; Patel K
    J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):662-686. PubMed ID: 30916493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
    Samant SA; Kanwal A; Pillai VB; Bao R; Gupta MP
    Sci Rep; 2017 Sep; 7(1):11877. PubMed ID: 28928419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscle NAD
    Hulmi JJ; Penna F; Pöllänen N; Nissinen TA; Hentilä J; Euro L; Lautaoja JH; Ballarò R; Soliymani R; Baumann M; Ritvos O; Pirinen E; Lalowski M
    Mol Metab; 2020 Nov; 41():101046. PubMed ID: 32599075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting.
    Zhou G; Gui X; Chen R; Fu X; Ji X; Ding H
    Clinics (Sao Paulo); 2019; 74():e981. PubMed ID: 31271588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle wasting in chronic kidney disease: the emerging role of microRNAs.
    Robinson KA; Baker LA; Graham-Brown MPM; Watson EL
    Nephrol Dial Transplant; 2020 Sep; 35(9):1469-1478. PubMed ID: 31603229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-noncoding RNA Atrolnc-1 promotes muscle wasting in mice with chronic kidney disease.
    Sun L; Si M; Liu X; Choi JM; Wang Y; Thomas SS; Peng H; Hu Z
    J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):962-974. PubMed ID: 30043444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of IL-1 in adipose browning and muscle wasting in CKD-associated cachexia.
    Cheung WW; Zheng R; Hao S; Wang Z; Gonzalez A; Zhou P; Hoffman HM; Mak RH
    Sci Rep; 2021 Jul; 11(1):15141. PubMed ID: 34302016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease.
    Yu R; Chen JA; Xu J; Cao J; Wang Y; Thomas SS; Hu Z
    J Cachexia Sarcopenia Muscle; 2017 Apr; 8(2):327-341. PubMed ID: 27897418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organ Crosstalk Contributes to Muscle Wasting in Chronic Kidney Disease.
    Wang XH; Price SR
    Semin Nephrol; 2023 Mar; 43(2):151409. PubMed ID: 37611335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
    Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
    Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription factor NRF2 as potential therapeutic target for preventing muscle wasting in aging chronic kidney disease patients.
    Gómez-García EF; Del Campo FM; Cortés-Sanabria L; Mendoza-Carrera F; Avesani CM; Stenvinkel P; Lindholm B; Cueto-Manzano AM
    J Nephrol; 2022 Dec; 35(9):2215-2225. PubMed ID: 36322291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice.
    Walton KL; Chen JL; Arnold Q; Kelly E; La M; Lu L; Lovrecz G; Hagg A; Colgan TD; Qian H; Gregorevic P; Harrison CA
    Endocrinology; 2019 Oct; 160(10):2417-2426. PubMed ID: 31322699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
    Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
    Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth Hormone Improves Adipose Tissue Browning and Muscle Wasting in Mice with Chronic Kidney Disease-Associated Cachexia.
    Mak RH; Gunta S; Oliveira EA; Cheung WW
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.